CD Genomics is dedicated to producing high-quality ChIP-seq data sets to help you profiling DNA targets for histone modification, structural proteins, transcription factors, and other DNA-associated proteins at a genome-wide scale.
The Introduction of ChIP-Seq
ChIP-Seq (chromatin immunoprecipitation sequencing), which refers to the binding site analysis, is a way to analyze DNA-protein interactions. The technique combines chromatin immunoprecipitation (ChIP) with NGS to identify where the DNA binds to the associated proteins. It can be used to pinpoint the binding sites of any interested protein throughout the genome. ChIP-seq is often used to determine how transcription factors and other chromatin-related proteins affect phenotypic mechanisms. Determining how proteins interact with DNA to regulate gene expression is essential to fully understand many biological processes and disease states. ChIP-Seq is a valuable tool for discerning and quantifying the specific DNA sequences where proteins bind or epigenetic modifications exist, it has played valuable roles in applications include studies on gene regulation, transcription complex assembly, DNA repair, histone modification, developmental mechanisms, disease progression and modifications.
- Gene regulation
- Transcription complex assembly
- DNA repair
- Histone modification
- Developmental mechanisms
- Disease progression
Advantages of ChIP-Seq
- Exceptionally high quality and high-resolution sequencing: It is possible to acquire millions of sequence tags and rare protein binding sites in the genome, ability to identify novel enrichment sites.
- Cost-effective: rapid and efficient genome-wide profiling of multiple samples in one run and only use 1/100 of the amount of DNA required for ChIP-chip.
- Comprehensive analysis: Utilizing widely accepted software and latest programs for motif prediction, peak annotation, functional analysis and data visualization of ChIP-Seq
A typical ChIP-Seq workflow is shown as follow:
|Sample requirements and preparation
- The original sequencing data
- Experimental results
- Data analysis report
- Details in ChIP-Seq for your writing (customization)
At CD Genomics, we provide you with high-quality sequencing and comprehensive bioinformatics analysis for your ChIP-Seq project, enabling accurately screen and determine the protein binding sites in the whole genome. If you have additional requirements or questions, please feel free to contact us.
1. What are the advantages of ChIP-Seq compared to ChIP-chip?
- ChIP-Seq enables genome-wide analysis, while ChIP-chip only analyzes parts of known sequences.
- ChIP-Seq provides accurate analysis of binding sequences, while ChIP-chip could not precise positioning.
2. What is the difference between sonication- and enzymatic-based chromatin fragmentation?
Either sonication or enzymatic digestion can be used to generate the appropriate lengths of chromatin. Sonication is a traditional method used for fragmenting chromatin, it uses acoustic energy to forcefully shear the chromatin. Sonicated chromatin works very well for performing ChIP to assess histones and histone modifications, however, over-sonication can damage the chromatin and displace bound transcription factors and cofactors. Therefore, sonication typically needs optimization. Enzymatic digestion uses micrococcal nuclease to cut the linker region between nucleosomes. It gently fragments the chromatin and preserves the integrity of chromatin and bound proteins. So it’s more suitable for performing ChIP to assess transcription factors and cofactors that are less abundant and interact with DNA less stable. In addition, enzymatic digestion provides better reproducibility between experiments. But over-digestion may lead to a loss of nucleosome-free regions.
3. Will high-resolution be guaranteed as long as high-throughput sequencing is used?
High throughput sequencing has greatly improved the resolution of ChIP detection, but it is not the only determinant of high resolution. After immunoenrichment, the length of fragments interrupted by chromatin also affects resolution.
4. What are the factors that lead to a higher false positive for ChIP-seq?
DNA fragmentation methods, heterogeneity of chromatin openness, PCR amplification bias, genome duplication, and errors in sequencing and sequence alignments lead to false positive. After sequencing, the sequences are compared to the known genome and identified the true binding sites (peaks). For transcription factors, look for the downstream regulatory gene (target gene) corresponding to the "peak" or construct a conserved binding sequence for the transcription factor binding site. If the motif of the transcription factor is known, calculate the percentage of the motif sequence in the "peak" sequence, and the reliability of the experimental results can be estimated.
ChIP-seq analysis of histone H3K9 trimethylation in peripheral blood mononuclear cells of membranous nephropathy patients
Journal: Brazilian Journal of Medical and Biological Research
Published: 12 December 2013
Membranous nephropathy (MN), characterized by the presence of diffuse thickening of the glomerular basement membrane and subepithelial in situ immune complex disposition, is the most common cause of idiopathic nephrotic syndrome in adults, with an incidence of 5-10 per million per year. A number of studies have confirmed the relevance of several experimental insights to the pathogenesis of human MN, but the specific biomarkers of MN have not been fully elucidated.
In this study, the authors used chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-seq) to analyze the variations in a methylated histone (H3K9me3) in peripheral blood mononuclear cells from 10 MN patients and 10 healthy subjects. There were 108 genes with significantly different expression in the MN patients compared with the normal controls. In MN patients, significantly increased activity was seen in 75 H3K9me3 genes, and decreased activity was seen in 33, compared with healthy subjects. Five positive genes, DiGeorge syndrome critical region gene 6 (DGCR6), sorting nexin 16 (SNX16), contactin 4 (CNTN4), baculoviral IAP repeat containing 3 (BIRC3), and baculoviral IAP repeat containing 2 (BIRC2), were selected and quantified. There were alterations of H3K9me3 in MN patients.
Table.1 ChIP-seq and alignment results.
Aligned reads: the number of reads refers to the reference genome; Aligned reads only: the number of reads only refers to the reference genome; % Aligned: aligned reads/total reads; % Only: aligned reads only/total reads.
Figure 1. ChIP-seq peak distribution (distance) of H3K9me3 from membranous nephropathy patients.
Figure 2. Genome-wide distribution of peaks relative to annotated genes.
Figure 3. Distribution of peaks relative genes by Gene Ontology (GO) analysis (AmiGO 1.8). The lateral axis represents the GO terminology. The left vertical axis represents the proportion of the related genes. The right vertical axis represents the number of the related genes.
Table 2. Basic information of motif of H3K9me3 from patients with membranous nephropathy.
S: C+G; R: A+G; K: T+G; Y: C+T; M: A+C; V: A+C+G.
Figure 4. ChIP-seq motif logo. The lateral axis indicates locus of motif. The total height of the vertical axis reflects the conservation of the motif. The height of each base represents probability of the base.
Table 3. Selected genes with H3K9me3 alterations between patients with membranous
nephropathy and healthy controls identified by ChIP-seq.
In summary, the authors think these results may be candidates to help explain pathogenesis in MN patients. Such novel findings show that H3K9me3 may be a potential biomarker or promising target for epigenetic-based MN therapies.
Sui W G, et al. ChIP-seq analysis of histone H3K9 trimethylation inperipheral blood mononuclear cells of membranous nephropathy patients. Brazilian journal of medical and biological research , 2014, 47(1):42-9.